+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID04511039

Phase I Study of TrifluridineTipiracil Combined with Talazoparib for Advanced or Metastatic Colorectal and Gastroesophageal Cancer

Led by Roswell Park Cancer Institute · Updated on 2026-05-04

45

Participants Needed

1

Research Sites

30 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety, best dose, and effects of combining the drugs talazoparib and trifluridinetipiracil in patients with locally advanced or metastatic colorectal or gastroesophageal cancer. This phase I trial aims to determine the maximum tolerated dose and recommended dose for further studies, while also assessing how the drugs behave in the body and their preliminary effectiveness against tumor growth. Participants receive trifluridinetipiracil by mouth twice daily and talazoparib by mouth once daily on days 1 through 5 of each cycle. Each treatment cycle lasts 14 days and repeats as long as the cancer does not progress and side effects remain manageable. The study focuses on evaluating the combination of these two oral chemotherapy drugs to inhibit tumor cell growth enzymes. During the study, participants will be regularly monitored for side effects after each 14-day cycle. Researchers will measure drug levels in the blood, track tumor response, progression-free survival, and overall survival for up to three years. Safety assessments will include monitoring adverse events and blood markers related to DNA damage. Participants are expected to continue treatment unless disease progression or unacceptable toxicity occurs.

CONDITIONS

Brief Title

Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer

Research Team

S

Sarah Chatley, BS

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here